Share Name Share Symbol Market Type Share ISIN Share Description
Frontier IP Group LSE:FIPP London Ordinary Share GB00B63PS212 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +1.00p +1.55% 65.50p 64.00p 67.00p 65.50p 65.50p 65.50p 11,198 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Nonequity Investment Instruments 0.3 1.2 3.7 17.6 20.16

Frontier IP Share Discussion Threads

Showing 51 to 75 of 75 messages
Chat Pages: 3  2  1
DateSubjectAuthorDiscuss
26/9/2018
18:06
Full page article on Alusid in the Times today. Doesn't say anything new, but good to see. Link requires registration or subscription - hTTps://www.thetimes.co.uk/edition/business/alusid-ceramics-the-start-up-that-had-the-kitchen-sink-thrown-at-it-fbjs5lm6h
elgordo
22/9/2018
12:17
just what the doctor ordered!!! lol! Frontier IP Group plc Amprologix to develop new antibiotics with Ingenza 20/09/2018 7:01am RNS Non-Regulatory TIDMFIPP Frontier IP Group plc 20 September 2018 RNS Reach AIM: FIPP 20 September 2018 Frontier IP Group Plc ("Frontier IP" or the "Group") New Portfolio Company - Amprologix to develop new antibiotics to help combat antimicrobial resistance in partnership with Ingenza Frontier IP, a specialist in commercialising university intellectual property, today announces it has taken a 10 per cent stake in Amprologix Limited ("the Company"), a spin-out from the University of Plymouth. The company has been established to introduce new antibiotics, helping to tackle antimicrobial resistance, a major threat to human health globally. It will develop and commercialise the work of Dr Mathew Upton, Professor in Medical Microbiology at the University's School of Biomedical Sciences. The first product from the Company is expected to be a cream containing epidermicin, one of the new antibiotics being developed to combat infections caused by antibiotic-resistant bacteria. Epidermicin can rapidly kill harmful bacteria including MRSA (methicillin resistant Staphylococcus aureus), Streptococcus and Enterococcus at very low doses, even if they are resistant to other antibiotics. No new classes of antibiotics have been introduced into clinical use for the past 30 years, and the company is aiming to meet a growing need for new antibiotics as harmful microbes become increasingly drug resistant. It has already secured industry involvement through a partnership with world-leading biotechnology and synthetic biology company Ingenza. The new company is focused on four areas: -- Developing epidermicin for commercial use -- Discovering additional sources for new classes of antibiotics -- Using Artificial Intelligence to improve antibiotic properties, working with Ingenza, IBM and the National Physical Laboratory -- Developing efficient techniques to manufacture antibiotics at scale in partnership with Ingenza In a relevant infection model, a single dose of epidermicin was as effective as six doses of the current standard of care. The antibiotic was initially recovered from a skin bacterium named Staphylococcus epidermidis, but can now be produced in a microbe suitable for industrial scale-up, using synthetic biology methods developed by Ingenza. Professor Upton initially developed the patented technology working closely with UMI3 Ltd at The University of Manchester, which now takes a 13 per cent stake in the new business. The World Health Organisation warned in February this year that "antibiotic resistance is one of the biggest threats to global health, food security, and development today". A UK government review in 2015, chaired by economist Jim O'Neill, estimated that by 2050, the global cost of antibiotic resistance will rise to US$100 trillion and drug resistant infections will cause 10 million deaths a year, eclipsing the current toll from cancer and diabetes combined. The government estimates there are currently 5,000 deaths each year in the UK because antibiotics no longer work for some infections. https://www.gov.uk/government/news/30-million-of-funding-to-tackle-antimicrobial-resistance Neil Crabb, chief executive of Frontier IP, said: "We are delighted to work with Amprologix to commercialise these potentially life-saving antibiotics, and with a leading industrial partner in the area. It is further sign our business model is gaining traction with universities and industry alike." Professor Mathew Upton, chief scientific officer of Amprologix, said: "It is very exciting to form a new company to take forwards our portfolio of novel antimicrobial compounds. Epidermicin, our lead candidate antibiotic, has excellent potential for treating and preventing serious, drug resistant infections. With our current team, the company will be the ideal vehicle to take epidermicin to the clinic." Dr Ian Fotheringham, managing director of Ingenza, said: "This unique partnership fully exploits the synergy of Ingenza's versatile bio-manufacturing technologies and Amprologix's lead in discovering exciting new antimicrobial classes, spearheaded by Dr Upton's innovative research." ENQUIRIES
uk2day
06/8/2018
18:03
Fieldwork Robotics agreement with Hall Hunter reported in today's The Times - hTTps://www.thetimes.co.uk/article/march-of-the-robots-was-never-so-sweet-l0mz6n3jl
elgordo
06/8/2018
16:11
Interview with Neil discussing the partnership with the Department for International Trade http://bit.ly/2KnDA7d
astonedt
20/7/2018
12:59
Neil Crabb spoke with DirectorsTalk about the Tarsis Technology’s collaboration with a world-leading crop protection company http://bit.ly/2zSfEsE
astonedt
17/7/2018
12:26
Interview & Q&A with CEO & Portfolio Manager: INTERVIEW - http://bit.ly/2upjjZA Q&A - http://bit.ly/2LrUhPY
astonedt
04/7/2018
16:16
Not making the ducks fly off the water,currently. f
fillipe
21/6/2018
11:19
Frontier IP Group's Neil Crabb discusses their 24% stake in Cambridge Materials Testing Solutions INTERVIEW - http://bit.ly/2taO5oB Q&A - http://bit.ly/2tfJeCq
astonedt
20/6/2018
09:59
Lol do you really have to create a new thread for a link?
uk2day
11/6/2018
10:14
Frontier IP Group portfolio company Molendotech featured in The Sun newspaper http://bit.ly/2sYajt4
astonedt
23/5/2018
12:31
CEO Neil Crabb talks to DirectorsTalk about a water testing kit developed by portfolio company Molendotech Interview - http://bit.ly/2rLPCk9 Q&A - http://bit.ly/2Gow0af
astonedt
27/3/2018
22:54
Summary from todays results rns! Frontier IP made good progress in pursuing growth and value for shareholders by: · Generating value from our relationships through working on new spin-outs, significant equity holdings and licensing income · Continuing to build a portfolio showing increasing signs of success · Reviewing and extending our pipeline for sources of high-quality intellectual property · Applying commercialisation expertise and leveraging our extensive network to help portfolio companies grow and achieve their business objectives Performance I am pleased to report we enjoyed an encouraging first half of the year across all areas of the business. Our core strategy is showing ever-more positive signs of delivering value and growth for our portfolio partners and shareholders. Fair value in our portfolio increased 19 per cent to £8,020,000 over the previous six months, representing year-on-year growth of 49 per cent. Pre-tax profits increased 67% to £524,000; cash at £1.85 million. Our continued growth was reflected in a highly successful capital markets day, held in Lisbon, Portugal, after the period end. This was attended by more than 70 participants including academics, industry, government, investors and a number of potential spin-out partners. Results Financial assets at fair value through profit and loss at 31 December 2017 increased to £8,020,000 (30 June 2017: £6,751,000; 31 December 2016: £5,396,000). Total revenue over the first half increased by 41% to £1,188,000 (2016: £843,000) reflecting the higher investment revaluations (unrealised) of £1,068,000 (2016: £711,000) while revenue from services decreased marginally to £120,000 (2016: £132,000). The profit before tax increased by 67% to £524,000 (2016: £314,000) reflecting the higher investment revaluations, partially offset by the higher administrative expenses. Administrative expenses increased by 26% to £667,000 (2016: £529,000) primarily reflecting increased staff, salaries and associated costs. Basic earnings per share was 1.17p (2016: 1.02p). Cash balances stood at £1,849,000 as at 31 December 2017 (30 June 2017: £2,329,000; 31 December 2016: £186,000). Net assets per share as at 31 December 2017 were 32.0p (30 June 2017: 30.7p; 31 December 2016: 26.0p).
uk2day
27/3/2018
22:41
Mon, 26th Mar 2018 07:00 RNS Number : 8368I Frontier IP Group plc 26 March 2018 Frontier IP Group plc [26] March 2018 FIPP RNS Reach Frontier IP Group Plc ("Frontier IP" or "the Group") Team Expansion and London Office Frontier IP Group, which specialises in intellectual property commercialisation, is pleased to announce it has appointed a communications professional to the team and is opening a new base in London. The moves provide a foundation for the next phase of the Group's growth. We are delighted to welcome Andrew Johnson, who will have responsibility for communications and investor relations across the Group's activities. Andrew has more than 20 years' journalism experience and is a former Deputy City Editor of the Daily Express. He has also worked for RBS. Andrew will be based in the City of London at our new offices at 18 King William Street, London, EC4N 7BP. I somehow missed this rns yesterday? I love the comment "The moves provide a foundation for the next phase of the Group's growth" a share price rise from 14p-85p in last 5yrs is growth im already over the moon with!, makes one wonder what increase in value and earnings come from the new base opening in London? and Fipp is still off the public radar! lol!
uk2day
22/2/2018
15:57
some nice chunky buys again today!!! something in the pipeline???
uk2day
19/2/2018
12:18
up we go!!!!!!
uk2day
19/2/2018
09:18
FIPP is completely off the radar!!!!!!!!!!!!! and still rising!! LOL!!!
uk2day
19/2/2018
08:51
another RNS not shown by ADVFN!!!!!!!!!!!!!!!! Monday 19 February, 2018 Frontier IP Group Portfolio News - Molendotech Secures First Funding RNS Number : 2030F Frontier IP Group plc 19 February 2018 FIPP RNS Reach Frontier IP Group Plc ("Frontier IP" or the "Group") Portfolio News - Molendotech Secures First Funding Frontier IP, which specialises in the commercialisation of intellectual property, is pleased to announce the completion of a first fundraising for portfolio company Molendotech Limited ("Molendotech" or "the Company"). Molendotech has received a commitment totalling £0.5 million which will be invested in three tranches. Frontier IP will hold approximately 14% of the issued share capital of Molendotech following the investment of the third tranche. Molendotech develops a novel test which is able to identify the concentration of faecal bacteria in water. Molendotech's rapid, point-of-use test to determine water quality enables more informed decision-making about the use of water and significantly improves the ability to identify and track any pollution source. The Company recently entered into a collaboration agreement with Palintest Limited ("Palintest"), a subsidiary of FTSE-100 company Halma plc, for the development and licencing of water testing products. This capital has been raised to support the development of further water testing products, initial sales and its expansion into new markets. Professor Simon Jackson, Director of Molendotech, said, "Securing significant investment at this early stage is a great achievement and confirmation of the commercial potential of Molendotech products. This funding will enable us to realise our business plans and develop a portfolio of water testing assays for different markets." Neil Crabb, Chief Executive of Frontier IP, said, "We are delighted that Molendotech has attracted significant backing so soon after its formation. This funding is a clear demonstration of confidence in both the technology and the stature of the partners it is able to bring in." For further information: Frontier IP Group Plc Neil Crabb, Chief Executive Company website: www.frontierip.co.uk T: 0131 240 1251 Cenkos Securities plc (Nominated Adviser and Joint Broker) Neil McDonald / Beth McKiernan T: 0131 220 6939 Peterhouse Corporate Finance Limited (Joint Broker) Lucy Williams T: 020 7469 0935 Kreab (Financial PR) Robert Speed / Matthew Jervois T: 020 7074 1800 Notes to Editor: About Frontier IP Group plc
uk2day
29/1/2018
17:04
Nice!!!!! todays rns! Frontier IP Group Plc Portfolio News - Molendotech Collaboration with Palintest Frontier IP, which specialises in the commercialisation of university intellectual property, is pleased to announce that portfolio company Molendotech Limited ("Molendotech"), a spin-out company from the University of Plymouth, has entered into a collaboration agreement with Palintest Limited ("Palintest"), a subsidiary of FTSE company Halma plc, for the development and licencing of water testing products. Molendotech has developed a novel test which is able to identify the concentration of faecal bacteria in water. Molendotech's rapid, point-of-use test to determine water quality enables more informed decision-making about the use of water and significantly improves the ability to identify and track any pollution source. Molendotech now aims to bring its product to market and to develop further products for the water testing market, in collaboration with Palintest. Professor Simon Jackson, Director of Molendotech, said, "We are delighted to announce our collaboration with Palintest, a market leader in water testing products. We are looking forward to working with Palintest to accelerate getting our products to market." Simon Bowman, Technical Director of Palintest, said, "We are very excited to be working with the Molendotech team and pleased to bring our own know-how and expertise to develop and commercialise the Molendotech technology." Neil Crabb, Chief Executive of Frontier IP, said, "Molendotech is showing strong potential and its technology is capable of addressing a wide range of water-testing applications from beaches to the beverage industry.
uk2day
29/1/2018
11:05
nice rise again today! 100p to be tested???
uk2day
25/1/2018
23:54
nice and peaceful on here! , no post since 6th dec and still climbing! lol!!! just how i like it!!!!!! A reminder of FIPP Key Strengths Portfolio offers strong capital growth potential Experienced management team Proactive in sourcing potential spin-outs Founder equity in return for support, not capital invested What Makes Us Different? Focus on doing the heavy lifting at a critical early stage rather than advising or investing, leaving inventors free to do what they do best Building a portfolio of technology companies where we have substantial (up to 40%) and “free” equity stakes Risk diversified across a wide range of technologies Ability to be opportunistic in working with sources of high-quality IP, through a mixture of formal and informal partnerships Opportunity Aiming to build on strong growth momentum in portfolio value - 7x growth in fair value of portfolio in four years (2011:2015) Shortage of similar very early-stage providers in the UK and continental Europe Increasing pressure on universities to demonstrate impact and generate fresh income streams Expanding into under-served markets in continental Europe, where third party commercialisation expertise is largely absent. just a reminder of why im invested and have been since as low as 14p!!! Nice!!!!!!
uk2day
25/1/2018
23:42
moving north again!! nice steady rises!!! news coming??? lubly jubly!!!!!!!!!!!!
uk2day
06/12/2017
16:02
Strong bump in advance of tomorrow's AGM. Just another Santa rally like last year, or hopefully something more tangible?
elgordo
09/5/2017
13:34
5% of a 250m EURO deal equates to 12.5m EURO or 10m sterling.Terribly worded initial rns
glenbo1
09/5/2017
13:23
Just got in here - should climb nicely this afternoon.
on target
09/5/2017
12:01
Wow great RNS ! certainly rising on the back of it now.
wolfcub
Chat Pages: 3  2  1
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:42 V: D:20181020 08:05:19